Sequella and Infectex announced positive results of a Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary TB (MDR-TB). SQ109 is a new small molecule drug discovered by scientists at Sequella and the US National Institutes of Health.
